Scott Carmer is the founder of NexImmune. NexImmune has raised $200M in total funding. Latest round: IPO. Backed by Multiple Myeloma Research Foundation.
Scott Carmer was the CEO at NexImmune, a Johns Hopkins incubated spin-out. He helped raise over $75M in Series A financing and grew the company from 8 to 75 employees. NexImmune went public in February 2021 through a $125M IPO. Prior to NexImmune, Carmer held senior leadership positions at companies such as Amgen, Genentech, MedImmune, and AstraZeneca.
Full founder directory · Investor directory · Company funding database · Fundraising library